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Duty to the Unborn:
A Response to Smolensky
JAIME KING*

In her article, Creating Children with Disabilities: Parental Tort
Liability for Preimplantation Genetic Interventions,' Kirsten Smolensky
examines the ever-expanding world of assisted reproductive technology
(ART) and the recent development of parental demand to use ART to
deliberately create children with disabilities The article explores the
potential for parental tort liability arising from both the use of
preimplantation genetic screening (indirect intervention), and genetic

manipulation (direct intervention). To summarize, Smolensky argues
that children are harmed by direct genetic manipulations that limit their
future capabilities, and should be able to sue their parents for their
losses. However, due to Parfit's Non-Identity Problem, selecting embryos
based on the presence of genes associated with limited future capabilities
(indirect intervention) should not incur tort liability.'
While Smolensky's basic premise that children should be able to sue

their parents for harmful preimplantation genetic manipulations is
sound, it both understates the potential scope of tort liability related to
preimplantation ART, and overstates the harm caused by genetic
manipulation to produce a child with a disabling condition. Part I of my
for direct
the parental demand
briefly considers
response
preimplantation genetic interventions to produce a child with disabilities.
* J.D., Ph.D., Associate Professor of Law, University of California, Hastings College of the
Law. I would like to thank Teneille Brown and Heather Field for their thoughtful comments on this
response.
i. Kirsten Rabe Smolensky, Creating Children with Disabilities: Parental Tort Liability for
PreimplantationGenetic Interventions,6o HASTINGS L.J. 299 (2008).
2. Susannah Baruch et al., Genetic Testing of Embryos: Practices and Perspectives of US IVF
Clinics, 89 FERTILTY & STERILITY 1053, 1055 (2008) (reporting that 3% of ART clinics surveyed in the
United States have enabled couples to select for children with disabilities); Darshak M. Sanghavi,
Wanting Babies Like Themselves, Some Parents Choose Genetic Defects, N.Y. TIMES, Dec. 5, 2006, at
F5.

3. See

DEREK PARFT, REASONS AND PERSONS

358-61 (rev. ed. 1987) (explaining that the Non-

Identity Problem argues that a child could not claim to be harmed if he or she was born into
disadvantageous circumstances or with a genetic disability because if his or her parents gave birth at a
more advantageous time or selected an embryo without a disability, the individual child would not
have been born); see also Smolensky, supra note i, at 301-02, 331-36.
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Part II examines the potential risks and benefits associated with
preimplantation decision making. Smolensky argues that limitations of a
child's future capacity constitute both moral and legal harms without
fully addressing the broader range of potential risks and benefits that can
result from preimplantation interventions.' The decision to use ART to
have a child with a disabling condition goes beyond the limitations
imposed on the child by the condition. It should also include the risks
inherent in using ART and the benefits of being born with a condition
into a culture that understands and supports it. Assessing the level of
harm requires balancing the full range of risks and benefits associated
with the choice, and giving strong consideration to the parents' attempt
to act in their child's best interests. Following this assessment of harm,
Part III considers the scope of parental liability under both intentional
and negligence-based tort claims. I argue in favor of Smolensky's
proposed "duty to act as a reasonably prudent parent"5 in reproductive
activities that occur outside the body of the mother, and, in turn,
broadening the scope of liability to include additional decisions made
during assisted reproduction. Finally, Part IV argues that even though
parental tort liability is possible, it does not provide the best mechanism
for assuring the welfare of children born through ART. Federal oversight
offers a more inclusive and widespread method of protecting this
population of future children.
I.

THE DEMAND FOR CHILDREN WITH DISABILITIES

As Smolensky notes, anecdotal and empirical research is beginning
to detect a small, but growing, desire among some parents to use ART to
enable them to have a child with a disabling trait. 6 From anecdotal
reports, parents have asked to select embryos with a narrow set of
conditions: deafness, achondroplasia (dwarfism),7 Down syndrome,' and
phenlyketonuria (PKU).9 While these disabilities and conditions may

4. Smolensky, supra note I, at 311-14,344-45.
5. Id. at 323 & n.136.

6. See id. at 304-06. See generally M. Spriggs, Lesbian Couple Create a Child Who Is Deaf Like
Them, 28 J. MED. ETHICS 283 (2000).

7. Achondroplasia is an autosomal dominant genetic disorder that results from a failure to
convert cartilage to bone. Achondroplasia -Genetics Home Reference, http://ghr.nlm.nih.gov/
condition=achondroplasia (last visited Dec. 15, 2oo8). Achondroplasia results in short arms and legs,
but a normal size trunk, and can be associated with apnea, obesity, and recurrent ear infections. Id.
8. Down syndrome is a chromosomal disorder that results from three copies of the twenty-first
chromosome, and is associated with impaired physical growth, reduced cognitive ability, congenital
heart defects, and distinctive facial features. Nat'l Inst. of Child Health & Human Dev., Down
Syndrome, http://www.nichd.nih.gov/health/topics/Down-Syndrome.cfm (last visited Dec. 15, 20o8).
9. PKU is an autosomal recessive disorder that increases levels of phenylalanine in the blood,
which at certain levels can cause mental retardation, seizures, behavioral problems, psychiatric
disorders, and other serious health problems. Phenylketonuria-Genetics Home Reference,
http://ghr.nlm.nih.gov/condition=phenylketonuria (last visited Dec. 15, 2oo8). PKU can successfully be
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limit the capabilities of a child, their symptoms are also controllable to a
level that children with them can still live worthwhile and fruitful lives.
Further, individuals with these conditions have created vibrant
communities with powerful cultural identities."
One reason parents want to use ART to create children with

disabilities is to have their children be a part of their own culture or
community." From a genetics standpoint, this is relevant to the potential
demand for genetic manipulation or gene therapy to have a child with a
disability. When both parents carry one of the above genetic conditions,
they have at least a 25%, and in some cases higher than 5o% 3 chance of
passing the disorder on to any given embryo. Therefore, a given cycle of

in vitro

fertilization

(IVF)

required

to

produce

embryos

for

preimplantation intervention will most likely produce at least one
embryo that carries the desired condition.'4 As a result, the majority of
parents with the above genetic conditions will produce an embryo with
the desired condition, thereby enabling them to engage in indirect
preimplantation genetic intervention, also known as preimplantation
genetic screening (PGS)," rather than having to manipulate their

treated through a special low-phenylalanine diet. Id.
Io. While their lives are restricted, individuals with all of these conditions go to school, hold jobs,
get married, etc.
Ti.

See generally PAUL PRESTON, MOTHER FATHER DEAF: LIVING BETWEEN SOUND AND SILENCE

(1994);
visited
visited
Down,

DeafLinx.com, Deaf Community, http://www.deaflinx.com/DeafCommunity/meet.html (last
Dec. 15, 2008); Down Syndrome Community, http://www.downsyndromecommunity.org (last
Dec. 15, 2008) (describing the Down syndrome Community in Washington state); Blogging
Blogging Down Syndrome-A Cooperative Blog, http://bloggingdown.com (last visited Dec.

15, 2008).

12. Sanghavi, supra note 2; Spriggs, supra note 6, at 283.

13. Parents who both have autosomal recessive disorders like PKU and some forms of congenital
deafness have close to a ioo% chance of passing the condition on to any given embryo, as both parents
must only have affected alleles. See Univ. of S. Dakota, Sanford Sch. of Med., Mendelian Patterns of
Inheritance, http://www.usd.edu/med/som/genetics/curriculum/iFMENDL4.htm (last visited Dec. 15,
2008). Parents with autosomal dominant disorders such as achondroplasia have a one-in-two chance of
passing the disorder to any given embryo, and because embryos that are homozygous for the condition
are nonviable, any viable embryo is twice as likely to have achondroplasia as it is to be normal. See
Achondroplasia-Genetics Home Reference, supra note 7. As a result, two-thirds of their
preimplantation embryos should carry the disorder. See id. Finally, while men and women with Down
syndrome tend to have reduced fertility levels, an individual with Down's has a 35% to 50% chance of
passing on the condition, while two parents with the disorder have an even higher chance of passing it
on to any given embryo. See Down's Syndrome Assoc., General FAQs, http://www.downssyndrome.org.uk/faqs/general-faqs.html (last visited Dec. 15, 2008).
14. See George B. Inge et al., Oocyte Number per Live Birth in IVF: Were Steptoe and Edwards
Less Wasteful?, 20 HuM. REPROD. 588, 589 tbls.I & II (2005) (demonstrating that in women under
thirty-eight treated at the Bourn Hall Clinic in 2000, low yield cycles (n= s18) produced on average one
to five oocytes, of which 57.6% became embryos, while intermediate cycles (n=44o) yielded six to
fifteen oocytes, of which 59.5% became embryos, and high yield cycles (n=121) produced sixteen or
more oocytes, of which 56.s % became embryos).
15. In this Essay, preimplantation genetic diagnosis (PGD) will refer to preimplantation testing
for a specific genetic or chromosomal disease. Preimplantation genetic screening (PGS) will refer to
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embryos' DNA to produce the condition. When both parents have the
genetic condition they desire for their child, the demand for direct
genetic manipulation to produce children with disabilities from which
parental tort liability could arise under Smolensky's analysis will be
extremely limited.
However, the demand for direct genetic manipulation may arise in
other contexts. First, deafness is not always hereditary. 6 Over 75% of
deafness results from nongenetic or nonfamilial causes,'7 and
approximately 90% of all children born to deaf parents are hearing."
Therefore, deaf parents with different etiologies may wish to use direct
genetic manipulation to have a deaf child. Secondly, as Smolensky noted
in her Down syndrome example, 9 in rare cases, parents who already
have a disabled child that resulted from a spontaneous mutation may
wish to have another child with the same disability to ease family
dynamics. For instance, parents who already have a child with PKU may
prefer a second child that also must adhere to the same strict diet, which
can simplify eating practices and meals. In cases of noncongenital causes
or spontaneous mutations, parents will not be able to use PGS to select a
child with the desired genetic condition. Therefore, having a child that
has the disorder will require direct genetic manipulation, which raises
significantly more ethical and regulatory implications.
Direct genetic manipulation or gene therapy has never been
attempted on a human embryo or a fetus. Research involving gene
therapy has mostly focused on adults and severely ill children, for whom
the risks of their current condition outweigh both the known and
unknown risks associated with gene therapy."0 Embryologists and
geneticists still have much to learn about the role of DNA and its
interaction with the uterine environment in the development of the fetus
and the child.' Altering the DNA of a preimplantation embryo at the
the use of preimplantation testing for all other conditions, as well as references that include both PGD
and PGS.
16. Even for parents who both have congenital deafness, the genes associated with their condition
may differ, thereby minimizing the ability to pass recessive traits to offspring.
I7. GALLAUDET RESEARCH INST., REGIONAL AND NATIONAL SUMMARY REPORT OF DATA FROM THE
2006-2007 ANNUAL SURVEY OF DEAF AND HARD OF HEARING CHILDREN AND YOUTH 2 (2006), available

at http://gri.gallaudet.edu/Demographics/2oo6_National-Summary.pdf (reporting that 26.1 % of survey
respondents were deaf from genetic/familial/hereditary causes).
18. PRESTON, supra note i i, at 13.
i9. Smolensky, supra note 1, at 304 (quoting Melissa Healy, Fertility's New Frontier: Advanced
Genetic Screening Could Help Lead to the Birth of a Healthy Baby, L.A. TIMES, July 21, 2003, § 6
(Health) at i).
20. See Adrian J. Thrasher & Robert G. Edwards, Averting Abnormal Inheritance: Potential of
Gene Therapy and PreimplantationGenetic Diagnosis, 8 REPROD. BIOMED. ONLINE 99, 100-02 (2003)
(on file with The Hastings Law Journal).
21. Gayane Ambartsumyan & Amander T. Clark, Aneuploidy and Early Human Embryo
Development, 17 HUM. MOL. GEN. (REVIEW ISSUE) Rio, RIO-I5 (2008).
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stem cell level may significantly affect the overall development of that
embryo and have numerous unanticipated consequences.22 Gene therapy
experimentation in humans has resulted in the untimely death of at least
two adult research participants due to overactive immune responses, as
well as the development of leukemia in others. 3 While research on gene
therapy in animal models is ongoing, the developmental and possible
long term health risks of gene therapy use in human preimplantation
embryos will most likely negate its use in the near term, until gene
therapy in adults has been improved significantly. 4
Regulation by the Food and Drug Administration (FDA) will
further stifle this market. Unlike PGS, gene therapy research is
extensively regulated within the United States. 5 Gene therapy differs
from PGS because it involves the creation of a biologic viral agent to
transfer the desired genes into the cell, while PGS only involves the use
of a genetic test.6 The addition of the biologic agent thrusts gene therapy
research into the FDA's regulatory purview. 7 The FDA's Center for
Biologics Evaluation and Research regulates research on all biologics,
prior to the sale and marketing of such products."' In order for a gene
therapy product to be sold for use in patients, the product would have to
be proven safe and effective, following a series of laboratory tests, animal
trials, and then human trials. 9 To start clinical trials in humans,
researchers must submit an investigational new drug (IND) application
to the FDA detailing the clinical trial protocol, the possible risks of the
trial, the measures it will take to protect patients, and the pre-clinical
data available to support moving forward to human trials.3" In addition,
as part of the IND process, researchers must obtain approval from an
Institutional Review Board (IRB), which will examine the risks and
benefits of the research and the ethical implications.3' In particular, the

22. Thrasher & Edwards, supra note 20, at 105 (stating that gene somatic cell gene therapy
techniques do not "differ greatly from cloning, with its frequent disasters in fetal life").
23. See id. at 102; Rick Weiss, Fungus Infected Woman Who Died After Gene Therapy, WASH.

POST, Aug. I7, 2007, at Aio; Brandon Keim, Gene Therapy: Is Death an Acceptable Risk?, WIRED,
Aug. 30, 2007, http://www.wired.comlmedtech/genetics/news/2oo7/08/gene-therapy.
24. Thrasher & Edwards, supra note 20, at 102-05.
25. U.S. Food & Drug Admin., Human Gene Therapy and the Role of the Food and Drug
Administration, Sept. 2000, http://www.fda.gov/CBER/infosheets/genezn.htm.
26. Id.
27. 21 C.F.R. § 312.21(a) (2008). While the FDA has the authority to regulate genetic tests, it has
not yet exercised this authority, leaving the genetic tests used for PGS largely unregulated. See 21
U.S.C. 321(h) (2006); see also Gail H. Javitt & Kathy Hudson, Genetics & Pub. Policy Ctr., Public
Health at Risk: Failures in Oversight of Genetic Testing Laboratories7-11 (2006), available at http://
www.dnapolicy.org/images/reportpdfs/PublicHealthAtRiskFinalWithCover.pdf.
28. 21 C.F.R. § 6ol.2.
29. Id.: see also id. §§ 61o.9-.i8.
30. Id. § 6oI.2.
31. Food & Drug Admin., supra note 25.
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FDA regulations require the IRB to ensure that the risks to subjects are
minimized, and that they are "reasonable in relation to the anticipated
benefits."32 Given this level of oversight and the cost of clinical trials, the
development of a gene therapy agent designed to excise normal DNA
and insert a DNA sequence to create a disabling condition seems
difficult to justify and unlikely to survive review. Furthermore, if created
and approved by the FDA, researchers who wanted to determine its
impact on the development of human embryos would also be subject to
the restrictions of the Dickey-Wicker Amendment, which limits the use
of federal research funds for research that may harm or destroy
embryos.33 Given the absence of federal funds to support such research,
the heavily regulated approval process for gene therapy products, and
the limited demand for a biological agent to insert DNA associated with
a particular disability into an otherwise normal embryo, few
biotechnology companies would consider producing such a product.
While the potential market for genetic manipulation to create a
disability will be extremely small, the demand for ART services in
general is not, and the demand for PGS continues to grow at a rapid
pace.34 Much of the growth in the use of ART has occurred despite risks
to the offspring involved.35 As a result, the potential scope of
Smolensky's parental tort liability arising from preimplantation

28 C.F.R. § 46.111 (2004).
33. The Dickey-Wicker Amendment currently prevents the use of federal funds for any activity
that involves "the creation of a human embryo or embryos for research purposes or research in which
human embryo or embryos are discarded, destroyed, or knowingly subjected to a risk of injury or
death greater than that allowed for research on fetuses in utero under 45 C.F.R. 2o8(a)(2) or 42 U.S.C.
289g(b)." Dickey-Wicker Amendment of 1996, Pub. L. No. 104-99, § 128, iio Stat. 26, 34 (1996)
(codified as amended in scattered sections of 42 U.S.C. and 45 C.F.R.).
32.

34. U.S.
ASSISTED

DEP'T OF HEALTH

REPRODUCTIVE

&

HUMAN SERVS.,

TECHNOLOGY

SUCCESS

CTRS. FOR DISEASE CONTROL & PREVENTION,

RATES: NATIONAL

SUMMARY AND

FERTILITY

2005
CLINIC

(Oct. 2007), available at http://www.cdc.gov/ART/ART2oo5/5o8PDF/2005ART5o8.pdf
(showing that the number of cycles of IVF more than doubled from 1996 to 2005); Baruch et al., supra
REPORTS 61

note 2, at 1054 (reporting that 45% of U.S. ART clinics provided approximately 3000 cycles of PGS in
2005).

35. Maryse Bonduelle et al., A Multi-Centre Cohort Study of the Physical Health of s-year-old
Children Conceived After Intracytoplasmic Sperm Injection, In Vitro Fertilization and Natural
Conception, 2o HuM. REPROD. 413, 416 (2005) (finding that 4.2% of children born via ICSI have a
major congenital malformation, which is 2.77 times the rate of children naturally conceived. This result
was partially due to increased defects in the urogenital system (3.7% ICSI, 2.1% IVF, 0.6% natural
conception)); Dorte Hvidtjorn et al., CerebralPalsy Among Children Born After In Vitro Fertilization:
The Role of Preterm Delivery-A Population-Based,Cohort Study, 118 PEDIATRICS 475, 478-79 (20O6)
(finding that IVF procedures that result in preterm deliveries posed an increased risk of cerebral
palsy); Reija Klemetti et al., Health of Children Born as a Result of In Vitro Fertilization. 118
PEDIATRICS 1819, 1823 (2006) (finding that singleton IVF babies had higher incidences of perinatal
problems, congenital malformations, and problems of the genitourinary system; interestingly, the
study also revealed a slight decrease in respiratory disease in children born via IVF compared to
naturally conceived controls (odds ratio o.86)).
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interventions could be broader than her article suggests. 6 On the other
hand, courts should also consider any potential benefits to the offspring
that may result from preimplantation interventions, a consideration that
may narrow the scope of tort liability. Only by examining the full range
of risks and benefits can juries accurately determine the parents' intent
or level of negligence in their preimplantation decision making.

II.

THE RISKS AND BENEFITS ASSOCIATED WITH PREIMPLANTATION
DECISIONS

Modern ART offers parents significantly more control over their
potential offspring than ever before. After deciding to create a child
through in vitro fertilization (IVF),37 parents' subsequent choices of what
to do with their preimplantation embryos pose a variety of risks and
benefits to the resultant child.
A.

RISKS ASSOCIATED WITH PREIMPLANTATION INTERVENTIONS

Smolensky unnecessarily constrains the scope of parental tort
liability that could arise from preimplantation actions by limiting her
discussion to genetic interventions and harms that limit a child's right to
an open future. Parental decisions during ART can create numerous
harms for which tort liability may be appropriate, even if those harms do
not limit the child's "right to an open future."" s Joel Feinberg's argument
that only those risks that threaten the child's right to an open future
should warrant legal protection stems from the challenge of claiming that
nonexistence would have been better than being born with the attendant
condition.39 While determining the level of damages appropriate for the
harm done by being born with a disability versus nonexistence may be on
the verge of "impossible" for courts,' determining the level of harm
between being born with a disabling condition versus being born without
one, or being born premature versus being born full-term, is more
feasible for courts. Plaintiffs may struggle to prove causation in some of

36. See generally Smolensky, supra note i, 318-39.
37. As noted by Smolensky, the Non-Identity Problem would also prohibit an argument by these
children that their parents had harmed them by undergoing IVF because the particular embryos they
developed from would not have existed otherwise. See Smolensky, supra note I, at 331-36.
38. The notion of a "child's right to an open future" was first discussed by Joel Feinberg in The
Moral Limits of the Criminal Law. I JOEL FEINBERG, THE MORAL LIMITS OF THE CRIMINAL LAW: HARM
TO OTHERS 99--102 (1984). The discussion by Buchanan and his coauthors, regarding the child's right to
an open future goes to the notion that parents should not close off their future children's abilities
through genetic choices in order to direct them into a certain life plan. This would not limit a tort claim
for physical harms that did not limit their right to an open future. ALLEN BUCHANAN ET AL., FROM
CHANCE TO CHOICE: GENETICS AND JUSTICE 170-72 (2000).

39.

FEINBERG, supra note

40.

Id. at ioi (quoting Williams v. New York, 223 N.E.2d 343, 344-45 (N.Y. 1966) (Keating, J.,

concurring)).

38.
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these cases, but that should not result in a complete bar on liability for
preimplantation decisions outside of direct genetic manipulation.
Since Smolensky limited her argument to examination of
preimplantation genetic decisions, employing a harm framework based
on child's right to an open future makes sense from an abstract
perspective. Her framework leaves ample room for parental expression
of privacy rights within preimplantation genetic decision making by
placing limits on parental choice only when the preferred choice would
"doom" the child's future interests.4 ' This approach aims to minimize the
need for challenging value judgments regarding which genetic conditions
parents can select for their children without incurring tort liability.
However, Feinberg's list of conditions that would violate a child's right to
an open future includes conditions that no longer seem to fit his
description of conditions that would doom the child's future interests to
"total defeat," such that the child had been wronged by being brought
into existence. The categorization of deafness and many of the other
conditions Feinberg lists seems entirely inconsistent with the experiences
of many people living with disabilities. 2 Therefore, the open future
framework may not still include some of the disabilities discussed in this
Essay, and continuing to include them will require juries to make value
judgments about which disabilities are so severe as to violate the child's
right to an open future.
While limiting parental tort liability to only those harms that violate
a child's right to an open future may make Smolensky's argument more
palatable to some, it eliminates claims for tort liability for some of the
most common and avoidable harms associated with preimplantation
interventions. 3 For instance, following IVF, prospective parents have the
ability to decide how many embryos to transfer to the uterus, whether to
engage in an embryo biopsy to test their preimplantation embryos for
genetic traits, and perhaps in the future, whether to engage in gene
therapy. Each of these decisions carries risks for prospective children
born through the procedure, which could also give rise to a tort claim
given the right set of circumstances.
i. Embryo Transfer
One of the largest risks to offspring born through IVF results from
the transfer of multiple embryos in a given IVF or PGS cycle.' While
ART clinicians often transfer more than one embryo to improve

41. Smolensky, supra note I, at 309 (citing FEINBERG, supra note 38, at 98).

supra note 38, at 98-99.
43. These risks are discussed below. See infra Part II.A.

42. FEINBERO,

44. See Michael Le Page, Fertility Experts Call for One Embryo per IVF Cycle, NEw ScIErTsT,
Oct.

18,

2006, http://www.newscientist.conchannel/sex/dn10326-fertility-experts-call-for-one-embryo-

per-ivf-cycle.html.
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pregnancy success rates, the practice increases the incidence of multiple
births from 3% with natural childbirth to 33% with IVF. 45 A recent study
of over 4500 children born through IVF found that children born from an
IVF multiple birth were nearly five times more likely to be born very
premature (less than thirty-two weeks) (9.6% versus 2%) or premature
(less than thirty-seven weeks) (49.2% versus 9.5%) as singleton IVF
births.46 IVF multiple births were also associated with significantly higher
rates of low birth weight (less than 2500 grams) (43.7% versus 6.5%) and
very low birth weight (less than I5OO grams) (8.2% versus 1.9%) babies,
as well as higher rates of respiratory problems (8.4% versus 2.0%),
hospitalization over seven days (47.4% versus io.8%) and perinatal
death (2.0% versus 0.9%). 4 1 In addition to newborn health complications,
premature babies are at risk for significant long-term disabilities, such as
mental retardation, cerebral palsy, lung and gastrointestinal problems,
and vision and hearing loss. 48 The additional risks to children born
through ART could easily be reduced or eliminated by transferring a
limited number of embryos per cycle.49
2. PreimplantationGenetic Testing and Embryo Biopsy
Preimplantation genetic testing also may create additional health
risks for embryos and prospective children. In order to conduct
preimplantation genetic tests for PGS, clinicians must conduct an embryo
biopsy to remove one to two cells from the embryo. 0 A number of
scientists have suggested that the embryo biopsy can significantly harm
the development of embryos, and may negatively affect the long-term
health of the resultant child.5' While clinical evidence suggests that babies

45. U.S. DEP'T OF HEALTH & HUMAN SERVS., CTRS. FOR DISEASE CONTROL & PREVENTION, supra
note 34, at 22.
46. Klemetti et al., supra note 35, at 1822.
47. Id.
48. Hvidtjrn, supra note 35, at 478-79 (finding that IVF procedures that result in preterm
deliveries posed an increased risk of cerebral palsy); March of Dimes, Fact Sheet-Preterm Birth,
http://www.marchofdimes.com/professionals/14332-I 157.asp (last visited Dec. 15, 2008).
49. In 2006, the American Society for Reproductive Medicine (ASRM) published guidelines
encouraging clinicians to limit the number of embryos transferred per cycle. Practice Comm., Soc'y for
Assisted Reprod. Tech. & Practice Comm., Am. Soc'y for Reprod. Med., Guidelines on Number of
Embryos Transferred, 86 FERTILrrY & STERILITY (SuPP 4) S5 I , S51 (2006). However, as I have argued
elsewhere, whether clinicians will abide by the ASRM guidelines remains questionable because
transferring fewer embryos reduces IVF success rates, which can harm ART clinic reputations and
require couples to go through additional cycles of IVF in order to establish a viable pregnancy. See
Jaime King, PredictingProbability:Regulating the Futureof PreimplantationGenetic Screening,8 YALE
J. HEALTH POL'Y L. & ETHICS 10, 123 n.ioo (2008).
5o . See, e.g., IVF-Infertility.com, Preimplantation Genetic Diagnosis (PGD), http://www.ivfinfertility.com/ivf/pgd.php (last visited Dec. i5, 2oo8).
51. Sebastiaan Mastenbroek et al., In Vitro Fertilizationwith Preimplantation Genetic Screening,
357 NEw ENG. J. MED. 9, 9 (2O07) (contemplating that the embryo biopsy may cause a significant
reduction in successful pregnancy rates for PGS patients compared with IVF patients);
PreimplantationGenetic Diagnosis Pioneersfrom the USA and Europe Refute New England Journal of
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born via PGS have similar health statistics to those born through IVF, 2
little information exists regarding the long-term impact of the embryo
biopsy on the development and health of the resulting offspring, as most
of them have not reached puberty. The known and unknown risks of
embryo biopsy should be weighed against the benefit of being able to
select between embryos. In cases of selecting for an embryo with a
disabling trait, establishing a benefit significant enough to outweigh the
risk of the procedure will be difficult. Harms derived from the embryo
biopsy required to conduct PGS provide an argument for potential
liability irrespective of Parfit's Non-Identity Problem, as those embryos
existed and could have been transferred without the removal of the cell
for genetic testing.
3. Direct Genetic Manipulationor Gene Therapy
While the data available regarding the risks associated with IVF and
PGS remain limited, no data on the risks associated with the use of direct
genetic manipulation or gene therapy in embryos exists, as the procedure
has never been attempted. Gene therapy holds substantial promise for
improving health care for millions of people suffering from genetic
disorders; however, translating this promise to practice has been
challenging. 3 The deaths of Jesse Gelsinger and Jolee Mohr following
participation in gene therapy trials, the development of "leukaemia-like
illnesses" in patients in the French SCID-XI clinical trial, and other
adverse events have hung like a black cloud over gene therapy research.54
However, researchers have made substantial progress in recent years,
leading to a resurgence in gene therapy research.5 Earlier this year,
Medicine Article,

MED. NEws TODAY, July sO, 2007, http://www.medicalnewstoday.com/articles/
76269.php (arguing that imprecise or unskilled embryo biopsies can be devastating to the embryo).
52. Children born via IVF have significantly worse health outcomes overall when compared with
children conceived naturally, and therefore the risks of engaging in IVF at all should be considered
when doing it solely for the purpose of producing a child with a specific disability. However, Parfit's
Non-Identity Problem would prevent children born through IVF from suing, as they would not
otherwise have been born. Klemetti, supra note 35, at 1822 (finding that overall IVF infants were more

likely to be born preterm (23.6% versus 5.5%), to have low birth weight (24% versus 4.8%), to require
treatment in the newborn intensive care unit (23% versus 8.2%), to require hospitalization for seven
days or more (23.8% versus 6.4%), and to die perinatally (.3% versus 0.6%) compared to naturally
conceived controls); see also M. Bonduelle et al, supra note 35; Jane Halliday, Outcomes of IVF
Conceptions:Are They Different?, 21 BEST PRAC. & RES. CLINICAL OBGYN 67, 67-68 (2oo7) (finding
that preterm delivery, low birth weight, and some birth defects occurred more frequently in singleton
children born through IVF than naturally conceived controls); King, supra note 49, at 122-26
(discussing these risks more in depth).
53. Thrasher & Edwards, supra note 2o, at ioo-o2.
54. Keim. supra note 23; Thrasher & Edwards, supra note 20, at 1o2; Weiss, supranote 23.
55. The NIH's Gene Modification Clinical Research Information System (GeMCRIS) shows So
currently active gene therapy trials in the United States, which represents an increase of forty-one new
trials from a year ago. Gene Modification Clinical Research Info. Sys., Gene Transfer Protocol
Reports, http://www.gemcris.od.nih.gov/Contents/GCCTRPTMAKER.asp
(last visited Dec. 15,
2008) (select "Active" under the scroll menu for "Status"; run search); cf Keim. supra note 23 (stating

December

2008]

DUTY TO THE UNBORN

initial safety trials on four adults to improve Leber's congenital
amaurosis, one form of congenital blindness, proved safe and effective in
the short term. 6 Researchers are making slow, but steady, progress in
areas of medicine where the risks associated with the disease at least
arguably outweigh the aggregate risks and uncertainties associated with
gene therapy. 7 For these conditions, gene therapy offers significant hope
for the future. But those are not the conditions Smolensky addresses. She
considers the use of gene therapy, which poses substantial risks even to
fully developed adults, for use in embryos for the sole purpose of
creating a child with a disability, which seems much more difficult to
justify given the current risks and benefits. 8 In fact, one gene therapy
researcher stated that the risks of gene therapy techniques used in
embryos would not "differ greatly from cloning, with its frequent
disasters in fetal life."59 Parents who wish to engage in direct genetic
manipulation to produce a child with a disabling trait should have a very
hard time finding a physician who would perform the procedure, and
proving to a jury that they did not intend to harm their child, or that they
acted as reasonably prudent parents. In this instance, Smolensky's
argument for parental tort liability is at its strongest.
In examining potential tort liability for parental preimplantation
interventions, courts should consider the medical risks of undertaking the
procedures necessary to enacting the parents' wishes. Whether their goal
is simply to have a child, to select a child who will or will not have a
specific disorder, or to alter the child's DNA to have or avoid a specific
condition, these risks shed light on parental intent as well as their
potential negligence. Including these risks broadens the scope of parental
tort liability for preimplantation interventions. However, the decision to
accept these risks or to opt to have a child with a disabling condition does
not occur in a vacuum. The existence of potential benefits to the children
of the procedure should also factor into a court's consideration of intent
and negligence.
B.

BENEFITS ASSOCIATED WITH PREIMPLANTATION DECISIONS

For parents, preimplantation decisions do not only include the risk
to the future child's health or his/her right to an open future, they also
that in August 2007, GeMCRIS reported 139 active trials).
56. James W.B. Bainbridge et al., The Effect of Gene Therapy on Visual Function in Leber's
Congenital Amaurosis, 358 NEW ENG. J. MED. 2231 (2OO8): Albert M. Maguire et al., Safety and
Efficacy of Gene Transfer for Leber's Congenital Amaurosis, 358 NEw ENG. J. MED 2240 (2008).
57. See, e.g., I.M. Germano et al., Gene Delivery by Embryonic Stem Cells for Malignant Glioma
Therapy: Hype or Hope?, 7 CANCER Bio. THERAPY 1341. 1345-46 (2008): Ju-mei Zhao et al., A
Promising Cancer Gene Therapy Agent Based on the Matrix Protein of Vesicular Stomatitis Virus, 22
FED'N AM. SOC'YS FOR EXPMT'L Bio. J. 4272, 4277-79 (2oo8); cf.Keim, supra note 23.

58. Smolensky, supra note i,at 301.
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contain the broader scope of family dynamics, economic realities, and
cultural norms. By not fully considering these factors, Smolensky's
argument overstates the harm associated with preimplantation genetic
manipulation to produce a child with a disabling condition. 6, If
researchers eliminate the risks associated with embryonic gene therapy,
in some instances, a reasonable parent, considering all of the risks and
benefits, could find that her child may have a better life with the
disability than without.
The argument for being born into the same cultural experience as
one's parents is strongest and most likely within the context of the Deaf
community, and for the sake of brevity, I will focus on it exclusively in
this section. In the absence of significant risks associated with gene
therapy, reasonable deaf parents could find that their child would have a
better life as a member of the Deaf community, than as a hearing child
permanently in between cultures. 6,
Many scholars and members of the Deaf community argue that
being deaf is not a disability. 6 In fact, only a small percentage of hearing
children born to deaf parents, who are intimately familiar with both the
Hearing and the Deaf cultures, believe that being unable to hear is
intrinsically disabling.6 Being deaf opens the door to membership in a
linguistic and cultural minority with a dynamic language, and a rich and
diverse population. 6' Deaf individuals maintain an extensive array of life
options and possible career paths. 6 Just as many hearing parents prefer
to raise hearing children, many deaf parents may believe that 66they are
better equipped to raise a child within their own cultural bounds.
In determining whether a harm has occurred, courts should weigh
the overall experience of being raised in the Deaf community against the
60. In her discussion of battery, Smolensky does not discuss the potential benefit to the child of
being born into his or her parents' culture or of the improved family dynamics. See Smolensky, supra
note i, at 318-20. However, she briefly raises this issue as a challenge to intentional battery claims in
her discussion of negligence. Id. at 321. In her discussion of negligence, she offers a solution in which
courts might emphasize that parents have wide discretion in child rearing and that would "protect
legitimate parental prerogatives," but never explicitly discusses the benefits that could result from a
parental decision to have a child with a disability and the necessity of balancing those risks and
benefits. ld. at 340 (quoting Parent-ChildImmunity: A Doctrine in Search of Justification, 50 FORDHAM
L. REV. 489, 526 (1982)).
61. I am using the Deaf community in this example because it provides the most likely case for
the use of genetic modification to have a child with a disabling trait.
62. Robert A. Crouch, Letting the Deaf Be Deaf Reconsidering the Use of CochlearImplants in
Prelingually Deaf Children, 27 HASTINGS CENTER REp. 14, 17 (1997) (arguing that the predominant
notion that the deaf are "merely and wholly disabled-is wrong and that we should quickly disabuse
ourselves of this ill-begotten notion").
63. PRESTON, supra note I I, at 227.
64. Id.
65. Anita Silvers, An Open Future, 27 HASTINGS CENTER REP. 5, 5 (1997).
66. Id. ("Being deaf does not foreclose legal, scientific, academic, acting, [or] music careers,
among others.").
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experience of being raised as a hearing child with deaf parents, as this
comparison more accurately represents the decision facing deaf parents.
More factors contribute to this analysis than just the loss of hearing. For
deaf parents, raising a hearing child presents many challenges involving
interpretation, cultural identity, education, and socialization. In his book,
Mother Father Deaf, Paul Preston recounts the experiences of 150
hearing children of deaf parents. 67 While these individuals had a variety
of positive and negative experiences, they discussed numerous difficult
family dynamics that may explain why some deaf parents prefer to have
deaf children. Hearing children born to deaf parents also bear significant
responsibilities for navigating the boundary between the Hearing and
Deaf cultures from a young age. Often the hearing children of deaf
parents are asked to interpret for their parents, and nearly all of them
had an "interpreting 'horror story"' in which they had to interpret for
their parents in an inappropriate situation, which ranged from a five or
six year old interpreting her mother's breast cancer diagnosis to a
teenager being asked to interpret for her parents' divorce proceedings, to
a child interpreting at her father's funeral. 6' Preston noted that over half
of the individuals he interviewed used "popular psychological terms to
describe their family obligations: 'premature duties,' ' arentified child,'
'overly responsible,' 'a little adult,' 'a lost childhood.''' While a number
of Preston's informants said that they were happy to take on additional
responsibilities to aid their parents, and that the added responsibilities
prepared them well for adulthood, others "felt they had been crushed by
their family responsibilities and by a family system that dissipated their
childhoods."7 At the conclusion of his book, Preston describes the
hearing children of deaf parents as
[P]eople without culture-straddling the land between the Deaf and
the Hearing. Their family experiences include both the normalcy of
deafness and the normalcy of hearing, the stigma of deafness and the
tyranny of hearing.
... [W]e speak with blended and broken voices .... We speak to
hearing parents and hearing educators who never fully understood or
accepted deafness, to deaf parents who were shut out of a Hearing
world and learned to reject and mistrust Hearing ways, and to the vast
majority of others who may learn from our struggles at finding out who
we are.

67.
68.
69.
70.
71.

PRESTON, supra note i i, at 4-5.
Id. at 146-47.
Id. at 15I.
Id. at 155.
Id. at 236-37.
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Courts should consider the role of these sentiments in the difficult
choices faced by parents in determining whether a preimplantation
battery or negligent act occurred.
Parents opting to undergo IVF and genetic manipulation to have a
child with a disabling condition incur significant personal expense and
discomfort to make these choices, and presumably they have given
extensive thought to their decision. The known requests for
preimplantation genetic selection encompass disabilities that enable
individuals to have a relatively full life, i.e., the ones for which a
reasonable person might successfully argue that the benefits of being a
part of a particular community might outweigh the reduction in the
child's open future. No parents have requested children with devastating
disorders such as Tay-Sachs72 or Fanconi anemia.73 For children with
these conditions, life is difficult, painful, and short. In the case of genetic
manipulation for a disability such as deafness or achondroplasia, courts
should consider the psychological impact on the child of being different
from their parents and their parents' culture, and the parents' ability to
successfully raise a child with such differences. These considerations can
significantly impact the scope of parental tort liability for both
intentional and negligence-based claims.
III. THE SCOPE OF PARENTAL TORT LIABILITY
A.

INTENTIONAL TORTS

While Smolensky is correct that intentional tort claims appear at
first to be the most appropriate for preimplantation interventions,
challenges associated with intentional tort claims make negligence claims
more viable. In single intent jurisdictions, the liability of parents to
children born through ART could be endless. Assisted reproduction
remains highly technical and fraught with opportunity for harm to the
embryo. If intent to contact the embryo will give rise to a battery claim
for any harmful or offensive result that occurs, many parents and
physicians may become significantly more reluctant to engage in IVF,
PGS, or genetic modification. While most courts remain unwilling to
entertain wrongful life claims by children suing for harms resulting from
the procedure that brought them life, such as IVF, children could still sue
for harms that result from genetic modification, transfer of multiple

72. Tay-Sachs is a serious genetic disorder that causes relentless deterioration of mental and
physical abilities, which typically causes death by the age of four. See, e.g., Medline Plus, Tay-Sachs
Disease, http://www.nlm.nih.gov/medlineplus/taysachsdisease.html (last visited Dec. 15, 2008).
73. Fanconi anemia is a rare, recessive blood disorder that leads to tumor growth and failure of
the bone marrow to produce blood cells. Many patients develop acute myelogenous leukemia and die
at a young age. Nat'l Heart Lung & Blood Inst., Diseases and Conditions Index, What Is Fanconi
Anemia?. Dec. 2007, http://www.nhlbi.nih.govlhealth/dci/Diseases/fanconi/fanconi-whatis.html.
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embryos, or embryo biopsy." Given the variable risks and benefits
involved for parents in making such preimplantation decisions,
permitting claims under battery in single intent jurisdictions seems
inappropriate to capture the nature of the decision, except in the most
egregious cases.
In dual intent jurisdictions, proving that the parents intended both
the contact and the harm also presents significant challenges. Such a
claim requires proving that the parents believed their actions would be
harmful to the future child. Few parents willing to go through the
physical rigors and expense of assisted reproduction would do so to
knowingly harm their child. In cases of direct genetic modification to
produce a disability, Smolensky argues that even though some parents
may not believe that the disability harms the child overall, courts should
use an objective standard of offense, rather than a subjective one.75 She
argues that:
Under an objective standard of offense, genetic traits such as deafness
or achondroplasia are almost certain to be considered offensive to a
reasonable sense of personal dignity. This is illustrated by the fact that

most people would be offended if they7 were unconscious and another
person removed their sense of hearing.

6

However, even an objective standard is not immune to specific
circumstance and context.77 Jurors should be asked to consider what a
reasonable person would do under similar circumstances. Of course a
reasonable hearing individual would object to being deafened without
their consent while unconscious, but whether a reasonable person would
find that deaf parents had intentionally harmed their child by rendering
it deaf before birth is more subtle and open to question. In addition, the
overall harm and perceived disability of never hearing is arguably less
than living in the hearing world and then losing the ability. Proving
intended harm in these cases will be more challenging than proving
negligence arising from engaging in a procedure when the risks
significantly outweighed the benefits.
B.

NEGLIGENCE

With respect to negligence, I support Smolensky's argument in favor
of creating a parental duty of care for preimplantation genetic
74. See, e.g., Walker ex rel. Pizano v. Mart, 790 P.2d 735, 741 (Ariz. 199o) (holding that a child
could not bring a "wrongful life" claim because no legally cognizable injury had occurred): Kassama v.
Magat, 792 A.2d 1102, 1116-17 (Md. 2002) (stating that twenty-eight other states have rejected
wrongful life claims). A handful of jurisdictions do permit wrongful life claims. See, e.g., Galvez v.
Frields, 107 Cal. Rptr. 2d 50, 57-59 (Cal. Ct. App. 2001); Harbeson v. Parke-Davis Inc.. 656 P.2d 483,
495 (Wash. 1983).
75. Smolensky, supra note i, at 319.

76. Id. 319-20.
77. JOHN C.P. GOLDBERG ET AL., TORT LAW: RESPONSIBILITIES AND REDRESS 557 (2d ed. 2008).
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interventions. However, I would broaden this argument to include all
ART choices made prior to embryo transfer, and account for the range
of risks and benefits of undergoing the procedure. Individuals should
owe a duty to their potential offspring to act as reasonably prudent
parents when making choices that do not conflict with the mother's
bodily integrity.78

Preimplantation decisions that occur outside the mother's body, and
therefore do not compromise the mother's bodily integrity, often have
serious implications for the health of the prospective child. Given the
complete level of control possessed by the parents, and the inability for
the child to assent, I agree with Smolensky that individuals undergoing
ART should have a duty to act as reasonably prudent parents.79 This duty
should require parents to weigh the risks and benefits of engaging in an
ART decision, and only engage in those activities that a reasonable
parent in similar circumstances would, given the attendant risks and
benefits to the prospective child. Guidelines for on the risks of engaging
in certain procedures, like multiple embryo transfer, embryo biopsy, and
embryonic genetic manipulation may assist physicians and parents in
determining which procedures are appropriate. When prospective
parents make ART decisions where the risks to their potential offspring
clearly outweigh the benefits and those risks materialize, the parents
should be liable in tort to their children. However, the threat of a
potential tort suit should not be the only detraction from or guidance on
appropriate uses of ART.
IV.

THE CASE FOR REGULATION

Although I agree with Smolensky that courts should permit lawsuits
by children against their parents for preimplantation decisions in certain
limited contexts, I disagree with her that tort liability may offer a better
mechanism than regulation for protecting children born through ART.
Since I have detailed my argument in favor of oversight for
preimplantation genetic screening and ART elsewhere,8° I will limit my
discussion of regulation here to three small points: discrimination against
the disabled, preemptive protection, and consistency.
First, Smolensky's argument against regulation stems from the
challenge of addressing the moral and eugenic issues that arise from
genetic selection and manipulation."' The disability community has
78. Protecting the mother's right to bodily integrity provides an important legal boundary for the
scope of parental tort liability for harm to their potential offspring. Smolensky gives a detailed
discussion of the role of bodily integrity in preimplantation decisions in her article, which I will not
recount here, but that I agree with. Id. at 325-28.
79. Id. at 323 & n.136.
8o. King, supra note 49.
8i. Smolensky, supra note i, at 300.
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expressed concern about any form of government regulation of genetic
testing for reproductive purposes, for fear that the government might
encourage individuals to select afainst embryos and fetuses with genes
associated with disabling traits. Adrienne Asch, a disability rights
advocate and scholar, has spoken out against any government regulation
proposing to list those conditions appropriate for reproductive genetic
testing." However, the creation of a regulatory agency that works with
representatives from the disability community to develop regulations for
the use of reproductive genetic testing could bring more light to their
experiences, values, and concerns than the action of a lay jury deciding
how much money to reward a child for being born with a disabling
condition. A large jury verdict in favor of a child against his parents for
creating him with the same disability they had could significantly increase
discrimination against members of the disability community.
While Smolensky presents a strong argument in favor of the lay
juror's ability to navigate the reasonable person standard, the lay
person's perception of the harm associated with a disabling trait may not
be representative of the harm actually experienced by the child. For
example, the experience of being deaf is more disabling for deaf children
of hearing parents than it is for deaf children of deaf parents. 84 Research
using data from test scores, teacher-counselor ratings, and family
interviews found that deaf children of deaf parents have more positive
self-evaluations, including self-esteem, self-confidence, and positive
adjustment to deafness, than deaf children of hearing parents.5 Positive
family climate toward deafness also makes a significant difference in the
child's overall self-image, and has a higher impact within families of deaf
parents and deaf children. 86 Likewise, research demonstrates that deaf
children in hearing families do not experience the same richness or
consistency of language input as that provided by hearing parents to
hearing children, or deaf parents to deaf children, which directly impacts
language comprehension and expression."' As a result, hearing
individuals' perception of the level of harm resulting from being deaf
may be significantly increased, even if they have a deaf child. While
leaving the decision of how harmful certain traits are to the tort system
avoids the risk of reverting to state-sponsored eugenics, society remains
82. See, e.g., JOSEPH P. SHAPIRO, No PITY: PEOPLE WITH DISABILTIES FORGING A NEW CIVIL RIGHTS
MOVEMENT 22-23 (1993).

83. Adrienne Asch, Disability Equality and Prenatal Testing: Contradictory or Compatible?, 30
FLA. ST. U. L. REV. 315,338-39 (2003).

84. Kathryn P. Meadow, Self-Image, Family Climate, and Deafness, 47 Soc. FORCES 428, 434-37
(1969).
85. Id. at 434.
86. Id.
87. Marc H. Bornstein et al., Representational Abilities and the Hearing Status of Child/Mother
Dyads, 70 CHILD DEV. 833,847-48 (i999).
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vulnerable to the much greater potential for ART to do through "the
collective impact of individual decision-making what governments have
imposed in the past in the name of bettering the human condition."
Second, in addition to a regulatory agency offering more of a voice
to the disability community, regulation offers ART children more
protection from harm. Smolensky argues that parental use of genetic
manipulation to create a child with a disabling condition creates both a
legal and moral harm.8' The crux of her argument depends on the genetic
manipulation limiting the child's "right to an open future."' Given the
passion with which she argues that using genetic manipulation to create a
disability constitutes a significant harm, I am surprised that she favors
tort liability over regulation. For the small number of children who may
find themselves in this situation, tort liability can only provide monetary
restitution; it cannot restore their capacity, nor reverse the harm. In
addition, restitution requires the child to sue his or her family members,
placing a great deal of strain upon intimate familial relationships. A
regulatory scheme that addressed all of assisted reproductive
technologies could preemptively limit PGS and gene therapy to choices
where the benefits outweighed the risks, and therefore go much further
toward protecting children from these types of harms.
Finally, a national regulatory scheme designed to govern all assisted
reproductive technologies, including PGS and gene therapy, would offer
parents and ART clinicians a consistent set of standards from which to
make decisions. Guidelines on appropriate care would strengthen
physician resolve against parental attempts to "strong-arm" them into
agreement.9' They would also provide parents with a consistent set of
expectations of the appropriate uses of various assisted reproduction
procedures based on their risks and benefits. Consistency in ART
regulation is of the utmost importance, as many patients travel out of
state to have the procedures.92 Otherwise, patients could travel across
state lines to have procedures that may result in tort liability after the
child is born in a different state.
I agree with Smolensky that creating national regulations may
encourage "medical tourism" and regulating genetic interventions
overseas will be extremely difficult. 3 However, what an individual may
do overseas has rarely sufficed as a reason not to regulate in the United

88. Michael Malinowski, Choosing the Genetic Makeup of Children: Our Eugenics Past-Present,
and Future?,36 CONN. L. REv. 125, 204 (2003) (footnote omitted).
89. Smolensky, supra note i, at 311-14.
9o. Id. at 309.
91. Id. at 305.
92. United States v. Wilson, 73 F.3d 675, 681 (7th Cir. 1995) (finding that there is substantial
interstate travel involved in reproductive health care).
93. Smolensky, supra note I, at 3o6.
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States. As a leader in ART, PGS and gene therapy, the standards we set
for ourselves will not only provide guidance to U.S. citizens about what
uses are safe, medically justifiable, and ethically appropriate, but they
will govern the development and use of these new technologies both in
the United States and abroad.
CONCLUSION

The rapid expansion of assisted reproductive technologies in the
United States will continue to raise challenging questions regarding the
boundaries of parental rights and responsibilities to their children.
Smolensky's article contributes to this growing literature by addressing
the scope of parental tort liability for preimplantation genetic
interventions. I agree with her proposal to create a parental duty to act as
reasonably prudent parents in similar preimplantation decision making.
Determining whether an individual acted as a reasonably prudent parent
should depend on the relative balance of risks and benefits involved in
the procedure. In the case of direct genetic manipulation to bring about a
disability, the jury should consider the risks of embryonic gene therapy,
the loss of function associated with the disability, and any potential
benefits for the child of having the disability. Such a duty would promote
the dissemination of information to parents on the risks associated with
using ART for different purposes and the potential consequences of their
decisions.
On the other hand, tort liability cannot adequately solve the legal,
ethical, and medical dilemmas associated with advances in assisted
reproduction on its own. An independent regulatory body that requests
input from a wide variety of citizens, including numerous members of the
disability community, will have a better opportunity to adequately
address the challenges of ART use as they arise, while still enabling
people to capitalize on the benefits of the technology. I am encouraged
by the rich debate that is beginning to exist within the legal literature
regarding the use and limits of ART, and hope it continues for some time
to come.
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